Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Capricor Therapeutics, Inc. has received a consensus rating of "Buy" from eight analysts, with a target price averaging $22.25.
• Institutional investors have significantly increased their stakes, with Tower Research Capital raising its position by 280.8% and BNP Paribas by 2,342.8% in the second quarter.
• The company's stock recently opened at $7.09, and it has a substantial market cap of $324.15 million despite reporting losses in its latest quarterly earnings.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has received a consensus rating of "Buy" from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $22.25.

CAPR has been the topic of a number of analyst reports. B. Riley initiated coverage on shares of Capricor Therapeutics in a research note on Thursday, June 26th. They issued a "buy" rating and a $21.00 price objective on the stock. Oppenheimer reduced their price objective on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating on the stock in a research note on Monday, June 23rd. Alliance Global Partners reaffirmed a "buy" rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. Roth Capital reduced their price objective on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating on the stock in a research note on Monday, July 14th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Capricor Therapeutics in a research note on Thursday.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its position in shares of Capricor Therapeutics by 280.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock valued at $67,000 after acquiring an additional 4,976 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Capricor Therapeutics by 2,342.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 36,398 shares of the biotechnology company's stock valued at $361,000 after acquiring an additional 34,908 shares during the period. Jump Financial LLC lifted its position in shares of Capricor Therapeutics by 42.6% during the 2nd quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company's stock valued at $2,309,000 after acquiring an additional 69,515 shares during the period. Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics during the 2nd quarter valued at $796,000. Finally, Rhumbline Advisers lifted its position in shares of Capricor Therapeutics by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company's stock valued at $531,000 after acquiring an additional 3,636 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $7.09 on Friday. The firm's fifty day moving average is $6.93 and its 200-day moving average is $9.35. Capricor Therapeutics has a 52 week low of $5.68 and a 52 week high of $23.40. The firm has a market cap of $324.15 million, a P/E ratio of -4.32 and a beta of 0.73.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. As a group, sell-side analysts anticipate that Capricor Therapeutics will post -1.21 earnings per share for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.